Search Results for

S1803

Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Continue Reading »

---

Search Again

• All Trial Categories Anal  (2) Bladder/Urinary Tract Cancer  (7)    Metastatic  (3)    Neoadjuvant  (3) Brain  (9)    Glioblastoma Multiforme (GBM)  (3)    Other Brain Tumors  (3) Breast  (9)    Breast Cancer Adjuvant  (3)    DCIS/LCIS  (1) Cancer Control/Symptom Management  (20) Carcinoid Tumors  (1) Colorectal Cancer  (8)    Metastatic  (2)    Rectal Neoadjuvant  (1) Esophageal Cancer  (1) Gall Bladder/ Biliary Tract Cancer  (1) Head/Neck Cancer  (5) Leukemia  (2)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (1) Liver/Hepatocellular Carcinoma  (1) Lung Cancer  (24)    Non-Small Cell Lung Cancer  (16)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (4)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (4)       Adjuvant Treatment for Resected NSCLC  (4)    Small Cell Lung Cancer  (8)       Extensive Stage SCLC  (5) Lymphoma  (2)    Non-Hodgkin’s Lymphoma  (1) MDS  (1) Melanoma  (1) Merkel Cell Carcinoma  (1) Multiple Myeloma  (1) Ovarian  (1) Pancreatic  (3)    Metastatic Disease  (2) Prostate  (9) Renal Cell/Kidney Cancer  (3)    Locally Advanced/Metastatic  (3) Sarcoma  (2)